Vertex: A Modest Dividend, A Solid Scheme

There’s CRISPR Therapeutics, a name that rolls off the tongue like a magician’s incantation. It’s the darling of the moment, the company everyone’s watching. But watching, my friends, doesn’t necessarily pay dividends. It’s a mid-cap, brimming with potential, yes, but potential is a slippery eel. For the risk-averse – those of us who prefer a steady income to a speculative gamble – there are alternatives. Consider Vertex Pharmaceuticals. A company that doesn’t promise the moon, but delivers a rather respectable lunar module.







